NAPP Logo
  • NAPP logo
  • About Us
  • Products
  • Working at Napp
    • Current vacancies
  • Partnering
    • Commercial partnering
    • Joint working
  • Education
    • Science Ambassador Scheme
    • NAPP Academy
  • Media
    • News
    • Press Releases
  • Contact
  • Home
  • About Us
  • Products
  • Working at Napp
  • Partnering
  • Education
  • Media
  • Contact

Press Releases

The below press releases have been approved for communication with medical press and media. For general Napp news, please visit our News page.

Image for Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes
Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes

July 2, 2020

Image for Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes

Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes

July 2, 2020

FOR UK MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY                         The European Commission (EC) approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Phase III renal outcomes trial, which was stopped early based on the achievement of a pre-specified efficacy criterion. Canagliflozin is the first therapy …
Read More
Image for CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes
CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes

May 29, 2020

Image for CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes
CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes

May 29, 2020

Image for Type 2 Diabetics miss out on a recommended annual kidney test which can signal irreversible damage that may lead to fatal complications, survey reveals
Type 2 Diabetics miss out on a recommended annual kidney test which can signal irreversible damage that may lead to fatal complications, survey reveals

February 20, 2020

Image for Type 2 Diabetics miss out on a recommended annual kidney test which can signal irreversible damage that may lead to fatal complications, survey reveals
Type 2 Diabetics miss out on a recommended annual kidney test which can signal irreversible damage that may lead to fatal complications, survey reveals

February 20, 2020

Image for Statement on the Public Health England Review on prescribed medicines that may cause dependence or withdrawal
Statement on the Public Health England Review on prescribed medicines that may cause dependence or withdrawal

September 10, 2019

Image for Statement on the Public Health England Review on prescribed medicines that may cause dependence or withdrawal
Statement on the Public Health England Review on prescribed medicines that may cause dependence or withdrawal

September 10, 2019

View all press releases

Stay connected

  • Legal
  • Cookie Policy
  • Privacy Notice
  • Registered Company
  • Modern Slavery Statement
  • Tax Strategy
  • Group Pension Scheme
  • Statement of Investment Principles
© 2020 NAPP Pharmaceuticals Limited
Last updated: May 2019

You are now leaving napp.co.uk. Napp does not accept any responsibility for the third party site.

Please click "Continue to external link" if you want to proceed.

Back to s://napp.co.uk
Continue to external link

This website uses cookies so that we can provide you with the best user experience possible.

 

Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

 

We use necessary cookies to ensure the proper functioning of our site.

 

We'd also like to set optional analytics cookies to help us to improve your experience when using the site. We won't set optional cookies unless you choose to enable them. Using this tool will place a cookie on your device which will remember your preferences when you next visit.

 

For more detailed information about the cookies we use, please refer to our Cookie Policy. Settings.

Napp
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy